HK1157337A1 - - Google Patents

Info

Publication number
HK1157337A1
HK1157337A1 HK11111670.1A HK11111670A HK1157337A1 HK 1157337 A1 HK1157337 A1 HK 1157337A1 HK 11111670 A HK11111670 A HK 11111670A HK 1157337 A1 HK1157337 A1 HK 1157337A1
Authority
HK
Hong Kong
Prior art keywords
cancer
therapy
compounds
useful
pharmaceutically acceptable
Prior art date
Application number
HK11111670.1A
Other languages
English (en)
Inventor
Maurizio Pulici
Fabio Zuccotto
Alessandra Badari
Stefano Nuvoloni
Giovanni Cervi
Gabriella Traquandi
Sonia Biondaro
Paolo Trifiro'
Chiara Marchionni
Michele Modugno
Original Assignee
Nerviano Medical Sciences Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41059486&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1157337(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nerviano Medical Sciences Srl filed Critical Nerviano Medical Sciences Srl
Publication of HK1157337A1 publication Critical patent/HK1157337A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK11111670.1A 2008-07-24 2011-10-28 HK1157337A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08161076 2008-07-24
PCT/EP2009/059506 WO2010010154A1 (fr) 2008-07-24 2009-07-23 3,4-diarylpyrazoles utilisés comme inhibiteurs de protéine kinase

Publications (1)

Publication Number Publication Date
HK1157337A1 true HK1157337A1 (fr) 2012-06-29

Family

ID=41059486

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11111670.1A HK1157337A1 (fr) 2008-07-24 2011-10-28

Country Status (20)

Country Link
US (2) US8541575B2 (fr)
EP (1) EP2324008B1 (fr)
JP (1) JP5385382B2 (fr)
CN (1) CN102105459B (fr)
AT (1) ATE557015T1 (fr)
AU (1) AU2009273197B2 (fr)
BR (1) BRPI0916356B1 (fr)
CA (1) CA2731146C (fr)
CL (1) CL2011000124A1 (fr)
CY (1) CY1117667T1 (fr)
DK (1) DK2324008T3 (fr)
EA (1) EA019722B1 (fr)
ES (1) ES2386408T3 (fr)
HK (1) HK1157337A1 (fr)
HR (1) HRP20120577T1 (fr)
MX (1) MX2011000738A (fr)
PL (1) PL2324008T3 (fr)
PT (1) PT2324008E (fr)
SI (1) SI2324008T1 (fr)
WO (1) WO2010010154A1 (fr)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008001943A1 (es) 2007-07-02 2009-09-11 Boehringer Ingelheim Int Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes.
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
PL2324008T3 (pl) * 2008-07-24 2012-09-28 Nerviano Medical Sciences Srl 3,4-diarylopirazole jako inhibitory kinazy białkowej
UY32146A (es) 2008-09-29 2010-04-30 Boehringer Ingelheim Int Derivados de las 5-[4-(1,5-dimetil-1h-pirazol-4-il)-1,2,3-triazol-1-il]-6-metil-nicotinamidas n-(sustituidas) y de las n-{5-[4-(1,5-dimetil-1h-pirazol-4-il)-1,2,3-triazol-1-il]-6-metil-piridin-3-il}-benzamidas sustituidas y composiciones conteniéndolos
JP2011057661A (ja) * 2009-08-14 2011-03-24 Bayer Cropscience Ag 殺虫性カルボキサミド類
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
CN104958294A (zh) 2010-01-27 2015-10-07 内尔维安诺医学科学有限公司 作为蛋白激酶抑制剂的3,4-二芳基吡唑的亚磺酰氨基衍生物
JP5871897B2 (ja) 2010-03-26 2016-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピリジルトリアゾール
EP2552905B1 (fr) 2010-03-26 2016-10-05 Boehringer Ingelheim International GmbH Inhibiteurs de la kinase B-Raf
AR081810A1 (es) 2010-04-07 2012-10-24 Bayer Cropscience Ag Piridinilpirazoles biciclicos
US20130096149A1 (en) * 2010-06-25 2013-04-18 Novartis Ag Heteroaryl compounds and compositions as protein kinase inhibitors
EP2601185B1 (fr) * 2010-08-03 2015-10-07 Nerviano Medical Sciences S.r.l. Dérivés de composés de pyrazolophényl-benzènesulfonamide et leur utilisation en tant qu'agents antitumoraux
TWI480276B (zh) * 2010-08-27 2015-04-11 Irm Llc 作為蛋白質激酶抑制劑之化合物及組合物
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
SG192126A1 (en) * 2011-01-25 2013-09-30 Univ Michigan Bcl-2/bcl-xl inhibitors and therapeutic methods using the same
US9199979B2 (en) 2011-02-24 2015-12-01 Nerviano Medical Sciences S.R.L. Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors
KR101298651B1 (ko) * 2011-03-16 2013-08-21 연세대학교 산학협력단 효능이 강화된 혈관신생 억제용 약제학적 조성물
JP6042896B2 (ja) 2011-10-06 2016-12-14 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 殺菌剤としての複素環ピリ（ミ）ジニルピラゾール
IN2014CN02475A (fr) 2011-10-06 2015-06-19 Bayer Ip Gmbh
RU2622015C2 (ru) 2011-11-11 2017-06-08 Новартис Аг Способ лечения пролиферативного заболевания
CA2856406C (fr) 2011-11-23 2020-06-23 Novartis Ag Formulations pharmaceutiques
JP6178861B2 (ja) 2012-11-02 2017-08-09 ファイザー・インク ブルトン型チロシンキナーゼ阻害剤
SG11201505525UA (en) 2013-01-16 2015-08-28 Univ Michigan Bcl-2bcl-xl inhibitors and therapeutic methods using the same
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
GB201410430D0 (en) 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
ES2918924T3 (es) 2015-04-01 2022-07-21 Rigel Pharmaceuticals Inc Inhibidores de TGF-beta
CA2993304C (fr) * 2015-08-03 2021-06-22 Glenmark Pharmaceuticals S.A. Nouveaux composes utilises en tant que modulateurs de ror gamma
EA201890730A1 (ru) 2015-09-16 2018-10-31 Локсо Онколоджи, Инк. Производные пиразолопиримидина в качестве ингибиторов btk для лечения злокачественного новообразования
EA035132B1 (ru) * 2015-12-16 2020-04-30 Локсо Онколоджи, Инк. Соединения, которые можно применять в качестве ингибиторов киназы
RU2759669C2 (ru) 2016-06-03 2021-11-16 Аррэй Байофарма Инк. Фармацевтические комбинации
BR112019005046A2 (pt) 2016-09-19 2019-06-18 Novartis Ag combinações terapêuticas compreendendo um inibidor de raf e um inibidor de erk
CN106883266B (zh) * 2017-01-23 2020-03-17 江苏七洲绿色化工股份有限公司 一种1-(4-氯苯基)-2-环丙基-1-丙酮的制备方法及其中间体
WO2019081485A1 (fr) 2017-10-26 2019-05-02 Bayer Cropscience Aktiengesellschaft Pyrazoles substitués, leurs sels et leur utilisation comme agents herbicides
WO2019081477A1 (fr) 2017-10-26 2019-05-02 Bayer Cropscience Aktiengesellschaft Pyrazoles substitués, leurs sels et leur utilisation comme agents herbicides
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
EP3870177A1 (fr) * 2018-10-26 2021-09-01 Arrien Pharmaceuticals LLC Composés de pyrazolyle et leurs procédés d'utilisation
WO2020168197A1 (fr) 2019-02-15 2020-08-20 Incyte Corporation Composés de pyrrolo[2,3-d]pyrimidinone en tant qu'inhibiteurs de cdk2
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
WO2020223558A1 (fr) 2019-05-01 2020-11-05 Incyte Corporation Composés aminés tricycliques en tant qu'inhibiteurs de cdk2
WO2020223469A1 (fr) 2019-05-01 2020-11-05 Incyte Corporation Dérivés de n-(1-(méthylsulfonyl)pipéridin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine et composés apparentés utilisés en tant qu'inhibiteurs de kinase 2 dépendante des cyclines (cdk2) pour le traitement du cancer
CA3142286A1 (fr) 2019-06-03 2020-12-10 Bayer Aktiengesellschaft Acides 1-phenyl-5-azinylpyrazolyl-3-oxyalkyliques et leur utilisation pour lutter contre la croissance de plantes adventices
WO2021030537A1 (fr) 2019-08-14 2021-02-18 Incyte Corporation Composés imidazolyl-pyrimidinylamines utilisés comme inhibiteurs de la cdk2
PE20221905A1 (es) 2019-10-11 2022-12-23 Incyte Corp Aminas biciclicas como inhibidoras de la cdk2
KR102323820B1 (ko) * 2019-10-31 2021-11-08 한국화학연구원 돌연변이형 idh 억제제, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물
CN112979613B (zh) * 2019-12-16 2022-04-26 四川大学华西医院 2-(1h-吡唑-3-基)吡啶衍生物及其制备方法和用途
EP4075979A1 (fr) 2019-12-19 2022-10-26 Bayer Aktiengesellschaft Acides 1,5-diphénylpyrazolyl-3-oxyalkyle et acides 1-phényl-5-thiénylpyrazolyl-3-oxyalkyle et leur utilisation pour lutter contre la croissance de plantes adventices
WO2021120890A1 (fr) * 2019-12-20 2021-06-24 Novartis Ag Dérivés pyrazolyle utiles en tant qu'agents anticancéreux
CN115003656A (zh) 2020-01-31 2022-09-02 拜耳公司 [(1,4,5-三取代1h-吡唑-3-基)硫烷基]乙酸衍生物和其盐及其作为活性除草成分的用途
WO2021202900A1 (fr) * 2020-04-02 2021-10-07 Plexxikon Inc. Composés de 1,6-naphtyridine et procédés de modulation de csk et leurs indications
BR112022021901A2 (pt) 2020-04-29 2023-01-17 Bayer Ag Ácidos de 1-pirazinilpirazolil-3-oxialquila e seus derivados e seu uso para controle de crescimento indesejado de planta
CN116368129A (zh) 2020-10-23 2023-06-30 拜耳公司 1-(吡啶基)-5-吖嗪基吡唑衍生物及其用于控制有害的植物生长的用途
IL302359A (en) * 2020-10-30 2023-06-01 Novartis Ag New crystalline forms of the KRAS G12C inhibitor compound
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
IL309609A (en) 2021-06-25 2024-02-01 Bayer Ag (5,4,1-trisubstituted-1H-pyrazol-3-yl)oxy-2-alkoxy alkyl acids and their derivatives, their salts and their use as herbicides
WO2023091873A1 (fr) * 2021-11-19 2023-05-25 The Board Of Trustees Of The University Of Illinois Effet épargnant des antibiotiques spécifiques à gram négatif sur microbiome intestinal
CA3240969A1 (fr) 2021-12-01 2023-06-08 Bayer Aktiengesellschaft Acides (1,4,5-trisubstitues-1h-pyrazole-3-yl)oxy-2-alcoxy alkyle et leurs derives, leurs sels et leur utilisation comme agents actifs herbicides
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2024078871A1 (fr) 2022-10-14 2024-04-18 Bayer Aktiengesellschaft Acides 1-pyridyl-5-phenylpyrazolyl-3-oxy- et -3-thioalkyl et leurs dérivés et leur utilisation pour lutter contre la croissance de plantes indésirables

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1246A (en) 1997-05-22 2004-02-07 Searle & Co Substituted pyrazoles as p38 Kinase inhibitors.
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
JP4399265B2 (ja) 2001-12-21 2010-01-13 ヴァーナリス（ケンブリッジ）リミテッド ３，４−ジアリールピラゾール、および癌の治療におけるそれらの使用
KR20060127032A (ko) * 2004-01-09 2006-12-11 노파르티스 아게 Ｉｇｆ―ｉｒ 억제제로서의페닐-[4-(3-페닐-1ｈ-피라졸-4-일)-피리미딘-2-일]-아민유도체
US20080242667A1 (en) 2005-08-26 2008-10-02 Smithkline Beecham Corporation Pyrimidinyl-Pyrazole Inhibitors of Aurora Kinases
EP2024353A2 (fr) * 2006-03-16 2009-02-18 Pfizer Products Inc. Pyrazoles
EP2057146A1 (fr) * 2006-10-02 2009-05-13 Irm Llc Composés et compositions utilisés en tant qu'inhibiteurs de protéine kinase
PL2324008T3 (pl) * 2008-07-24 2012-09-28 Nerviano Medical Sciences Srl 3,4-diarylopirazole jako inhibitory kinazy białkowej
CN104958294A (zh) * 2010-01-27 2015-10-07 内尔维安诺医学科学有限公司 作为蛋白激酶抑制剂的3,4-二芳基吡唑的亚磺酰氨基衍生物
EP2601185B1 (fr) 2010-08-03 2015-10-07 Nerviano Medical Sciences S.r.l. Dérivés de composés de pyrazolophényl-benzènesulfonamide et leur utilisation en tant qu'agents antitumoraux

Also Published As

Publication number Publication date
JP5385382B2 (ja) 2014-01-08
ATE557015T1 (de) 2012-05-15
SI2324008T1 (sl) 2012-08-31
HRP20120577T1 (hr) 2012-08-31
US20110144068A1 (en) 2011-06-16
MX2011000738A (es) 2011-02-23
PL2324008T3 (pl) 2012-09-28
US8946250B2 (en) 2015-02-03
ES2386408T3 (es) 2012-08-20
CN102105459B (zh) 2014-09-10
CL2011000124A1 (es) 2011-05-06
EA019722B1 (ru) 2014-05-30
AU2009273197B2 (en) 2014-01-16
EA201170249A1 (ru) 2011-10-31
AU2009273197A2 (en) 2011-03-10
CN102105459A (zh) 2011-06-22
DK2324008T3 (da) 2012-07-23
EP2324008A1 (fr) 2011-05-25
CA2731146C (fr) 2016-05-03
AU2009273197A1 (en) 2010-01-28
CA2731146A1 (fr) 2010-01-28
BRPI0916356B1 (pt) 2022-08-23
CY1117667T1 (el) 2017-05-17
PT2324008E (pt) 2012-06-25
US20140005150A1 (en) 2014-01-02
WO2010010154A1 (fr) 2010-01-28
EP2324008B1 (fr) 2012-05-09
US8541575B2 (en) 2013-09-24
BRPI0916356A2 (fr) 2018-08-21
JP2011528698A (ja) 2011-11-24

Similar Documents

Publication Publication Date Title
HK1157337A1 (fr)
HK1136292A1 (en) Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
WO2009071480A3 (fr) Dérivés de dihydroptéridin-6-one substitués, procédé de préparation desdits dérivés et leur utilisation en tant qu'inhibiteurs de kinase
UA99141C2 (ru) Замещенные производные индазола, активные в качестве ингибиторов киназы
MX2009006401A (es) Derivados de indazol como inhibidores de cinasa para el tratamiento del cancer.
MY142019A (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
PH12016501394A1 (en) Compounds for treating patients with ros1 mutant cancer cells
MXPA06000302A (es) Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden.
ATE514699T1 (de) Substituierte pyrrolopyrazolderivate als kinaseinhibitoren
UA94097C2 (ru) Пиридил- и пиримидинилзамещенные производной пиррола, тиофена и фурана как ингибиторы киназ
BRPI0413427A (pt) derivados de piridilpirrol ativos como inibidores da cinase
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
MX2009010059A (es) Derivados de quinolina para el tratamiento de enfermedades inflamatorias.
WO2009007749A3 (fr) Composés 947
MX2010003927A (es) Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteinas cinasas b.
TW200510385A (en) Pyrrolo[3, 4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
UA104988C2 (uk) Похідні піроніндолу та спосіб їх отримання
BRPI0413438A (pt) derivados de pirimidilpirrol ativos como inibidores de cinase
UA102219C2 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применения как ингибиторов киназы
CU23596A3 (es) Derivados de pirazol-quinazolina y proceso para su preparación
UA100390C2 (en) Pyrrolo[2,3-d]pyrimidin derivatives as protein kinase b inhibitors